Oncolytics jumps on Phase III tumor effect data for Reolysin
This article was originally published in Scrip
Executive Summary
Oncolytics Biotech continues to provide incremental updates on its Phase III clinical trial in head and neck cancer for Reolysin, the Canadian company's proprietary formulation of the human reovirus, with topline data for one of the double-blind, randomized trial's endpoints: the percentage change in tumors between pre-treatment and post-first treatment scans.